Citations

Clear

4610 citation(s) found for "Lu, Brian".

Increased Reactive Oxygen Species Production and Lower Abundance of Complex I Subunits and Carnitine Palmitoyltransferase 1B Protein Despite Normal Mitochondrial Respiration in Insulin-Resistant Human Skeletal Muscle
Lefort, Natalie , Glancy, Brian , Willis, Wayne T. , Bailowitz, Zachary, Filippis, Elena A. De, Brophy, Colleen M., Højlund, Kurt , Yi, Zhengping , Mandarino, Lawrence J. , Bowen, Benjamin P. , Meyer, Christian , Glancy, Brian

Mayo Clinic

Diabetes | August 4, 2010 | Volume: 59 | Issue: 10 | Pages: 2444-2452

10.2337/db10-0174 | PMID 20682693 Get It

OBJECTIVE The contribution of mitochondrial dysfunction to skeletal muscle insulin resistance remains elusive. Comparative proteomics are being applied to generate new hypotheses in human biology and were applied here to isolated mitochondria to identify novel changes in mitochondrial protein abundance present in insulin-resistant muscle. RESEARCH DESIGN AND METHODS Mitochondria were isolated from vastus lateralis muscle from lean and insulin-sensitive individuals and from obese and insulin-resistant individuals who were otherwise healthy. Respiration and reactive oxygen species (ROS) production rates were measured in vitro. Relative abundances of proteins detected by mass spectrometry were determined using a normalized spectral abundance factor method. RESULTS NADH- and FADH2-linked maximal respiration rates were similar between lean and obese individuals. Rates of pyruvate and palmitoyl-dl-carnitine (both including malate) ROS production were significantly higher in obesity. Mitochondria from obese individuals maintained higher (more negative) extramitochondrial ATP free energy at low metabolic flux, suggesting that stronger mitochondrial thermodynamic driving forces may underlie the higher ROS production. Tandem mass spectrometry identified protein abundance differences per mitochondrial mass in insulin resistance, including lower abundance of complex I subunits and enzymes involved in the oxidation of branched-chain amino acids (BCAA) and fatty acids (e.g., carnitine palmitoyltransferase 1B). CONCLUSIONS We provide data suggesting normal oxidative capacity of mitochondria in insulin-resistant skeletal muscle in parallel with high rates of ROS production. Furthermore, we show specific abundance differences in proteins involved in fat and BCAA oxidation that might contribute to the accumulation of lipid and BCAA frequently associated with the pathogenesis of insulin resistance.
Dyssynchrony Indices To Predict Response to Cardiac Resynchronization Therapy
Miyazaki, Chinami , Redfield, Margaret M. , Powell, Brian D. , Lin, Grace, Herges, Regina M., Hodge, David O. , Olson, Lyle J. , Hayes, David L. , Espinosa, Raúl E. , Rea, Robert F., Nelson, Susan M., Miller, Fletcher A., Oh, Jae K. , Bruce, Charles J.

Mayo Clinic

Circulation: Heart Failure | July 21, 2010 | Volume: 3 | Issue: 5 | Pages: 565-573

10.1161/circheartfailure.108.848085 | PMID 20647479 Get It

Background— Whether mechanical dyssynchrony indices predict reverse remodeling (RR) or clinical response to cardiac resynchronization therapy (CRT) remains controversial. This prospective study evaluated whether echocardiographic dyssynchrony indices predict RR or clinical response after CRT. Methods and Results— Of 184 patients with heart failure with anticipated CRT who were prospectively enrolled, 131 with wide QRS and left ventricular ejection fraction <35% had 6-month follow-up after CRT implantation. Fourteen dyssynchrony indices (feasibility) by M-mode (94%), tissue velocity (96%), tissue Doppler strain (92%), 2D speckle strain (65% to 86%), 3D echocardiography (79%), and timing intervals (98%) were evaluated. RR (end-systolic volume reduction ≥15%) occurred in 55% and more frequently in patients without (71%) than in patients with (42%) ischemic cardiomyopathy ( P =0.002). Overall, only M-mode, tissue Doppler strain, and total isovolumic time had a receiver operating characteristic area under the curve (AUC) greater than the line of no information, but none of these were strongly predictive of RR (AUC, 0.63 to 0.71). In nonischemic cardiomyopathy, no dyssynchrony index predicted RR. In ischemic cardiomyopathy, M-mode (AUC, 0.67), tissue Doppler strain (AUC, 0.79), and isovolumic time (AUC, 0.76) -derived indices predicted RR ( P <0.05 for all), although the incremental value was modest. No indices predicted clinical response assessed by Minnesota Living with Heart Failure Questionnaire, 6-minute walk distance, and peak oxygen consumption. Conclusions— These findings are consistent with the Predictors of Response to CRT study and do not support use of these dyssynchrony indices to guide use of CRT.
Iodixanol Versus Low-Osmolar Contrast Media for Prevention of Contrast Induced Nephropathy
From, Aaron M., Badarin, Firas Al , McDonald, Furman S., Bartholmai, Brian J. , Cha, Stephen S., Rihal, Charanjit S. , Cha, Stephen S., Rihal, Charanjit S. , Bartholmai, Brian J

Mayo Clinic

Circulation: Cardiovascular Interventions | July 21, 2010 | Volume: 3 | Issue: 4 | Pages: 351-358

10.1161/circinterventions.109.917070 | PMID 20647563 Get It

Background— Contrast-induced nephropathy (CIN) is associated with significant morbidity and mortality. The objective of our meta-analysis was to assess the efficacy of iodixanol compared with low-osmolar contrast media (LOCM) for prevention of CIN. Methods and Results— We searched MEDLINE, the Cochrane Central Register of Controlled Trials, and internet sources of cardiology trial results for individual and relevant reviews of randomized, controlled trials, for the terms contrast media, contrast nephropathy, renal failure, iodixanol, Visipaque, and low-osmolar contrast media. All studies reported an incidence rate of CIN for each study group; there was no restriction on the definition of CIN. There were no restrictions on journal type or patient population. Overall, 36 trials were identified for analysis of aggregated summary data on 7166 patients; 3672 patients received iodixanol and 3494 patients received LOCM. Overall, iodixanol showed no statistically significant reduction in CIN incidence below that observed with heterogeneous comparator agents ( P =0.11). Analysis of patient subgroups revealed that there was a significant benefit of iodixanol when compared with iohexol alone (odds ratio, 0.25; 95% confidence interval, 0.11 to 0.55; P <0.001) but not when compared with LOCM other than iohexol or with other ionic dimers or among patients receiving intra-arterial contrast injections or among patients undergoing coronary angiography with or without percutaneous intervention. Conclusions— Analysis of aggregated summary data from multiple randomized, controlled trials of iodixanol against diverse LOCMs for heterogeneous procedures and definitions of CIN show an iodixanol-associated reduction that is suggestive but statistically nonsignificant.
Operating Room Pooling and Parallel Surgery Processing Under Uncertainty
Batun, Sakine , Huschka, Todd R., Schaefer, Andrew J. , Denton, Brian T.

Mayo Clinic

INFORMS Journal on Computing | July 3, 2010 | Volume: 23 | Issue: 2 | Pages: 220-237

10.1287/ijoc.1100.0396 Get It

Operating room (OR) scheduling is an important operational problem for most hospitals. In this study, we present a novel two-stage stochastic mixed-integer programming model to minimize total expected operating cost given that scheduling decisions are made before the resolution of uncertainty in surgery durations. We use this model to quantify the benefit of pooling ORs as a shared resource and to illustrate the impact of parallel surgery processing on surgery schedules. Decisions in our model include the number of ORs to open each day, the allocation of surgeries to ORs, the sequence of surgeries within each OR, and the start time for each surgeon. Realistic-sized instances of our model are difficult or impossible to solve with standard stochastic programming techniques. Therefore, we exploit several structural properties of the model to achieve computational advantages. Furthermore, we describe a novel set of widely applicable valid inequalities that make it possible to solve practical instances. Based on our results for different resource usage schemes, we conclude that the impact of parallel surgery processing and the benefit of OR pooling are significant. The latter may lead to total cost reductions between 21% and 59% on average.
HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica
Matiello, Marcelo , Schaefer-Klein, Janet, Brum, Doralina Guimarães , Atkinson, Elizabeth J. , Kantarci, Orhun H. , Weinshenker, Brian G. , collaborators, the NMO genetics, Weinshenker, Brian G

Mayo Clinic

Multiple Sclerosis Journal | June 30, 2010 | Volume: 16 | Issue: 8 | Pages: 981-984

10.1177/1352458510374340 | PMID 20591987 Get It

Background: Association of the HLA-DRB1*1501 allele with multiple sclerosis is well established, but its association with neuromyelitis optica has only been evaluated in small populations. Methods: We performed a case-control genetic association study to evaluate the association of HLA-DRB1*1501 with neuromyelitis optica. The single nucleotide polymorphism rs3135388, which tags HLA-DRB1*1501, was genotyped in 164 patients with neuromyelitis optica, 220 patients with multiple sclerosis and 959 controls matched for age, gender and ethnicity. Genotyping for rs3135388 was performed by Taqman-based 5' nuclease assay. Results: Rs3135388*A was positively associated with multiple sclerosis (OR = 3.93; 95% CI = 2.58—5.97, p = 1.18 × 10 -09 ) but negatively associated with NMO (OR = 0.57; 95% CI = 0.36—0.91, p = 0.01). Conclusions: Multiple sclerosis and neuromyelitis optica differ in their associations with DRB1*1501.
Regulation of Circulating Progenitor Cells in Left Ventricular Dysfunction
Boilson, Barry A. , Larsen, Katarína, Harbuzariu, Adriana , Delacroix, Sinny , Kořínek, Josef , Froehlich, Harald , Bailey, Kent R. , Scott, Christopher G. , Shapiro, Brian P. , Boerrigter, Guido, Chen, Horng H. , Redfield, Margaret M. , Burnett, John C. , Simari, Robert D., Scott, Christopher

Mayo Clinic

Circulation: Heart Failure | June 24, 2010 | Volume: 3 | Issue: 5 | Pages: 635-642

10.1161/circheartfailure.109.879437 | PMID 20573992 Get It

Background— Reductions in numbers of circulating progenitor cells (CD34+ cell subsets) have been demonstrated in patients at risk for, or in the presence of, cardiovascular disease. The mediators of these reductions remain undefined. To determine whether neurohumoral factors might regulate circulating CD34+ cell subsets in vivo, we studied complementary canine models of left ventricular (LV) dysfunction. Methods and Results— A pacing model of severe LV dysfunction and a hypertensive renal wrap model in which dogs were randomized to receive deoxycorticosterone acetate (DOCA) were studied. Circulating CD34+ cell subsets including hematopoietic precursor cells (HPCs: CD34+/CD45 dim /VEGFR2−) and endothelial progenitor cells (EPCs: CD34+/CD45−/VEGFR2+) were quantified. Additionally, the effect of mineralocorticoid excess on circulating progenitor cells in normal dogs was studied. The majority of circulating CD34+ cells expressed CD45dimly and did not express VEGFR2, consistent with an HPC phenotype. HPCs were decreased in response to pacing, and this decrease correlated with plasma aldosterone levels (Spearman rank correlation=−0.67, P =0.03). In the hypertensive renal wrap model, administration of DOCA resulted in decreased HPCs. No changes were seen in EPCs in either model. Normal dogs treated with DOCA exhibited a decrease in HPCs in peripheral blood but not bone marrow associated with decreased telomerase activity. Conclusions— This is the first study to demonstrate that mineralocorticoid excess, either endogenous or exogenous, results in reduction in HPCs. These data suggest that mineralocorticoids may induce accelerated senescence of progenitor cells, leading to their reduced survival and decline in numbers.
Holmium Laser Enucleation of the Prostate: Efficiency Gained by Experience and Operative Technique
Dusing, Michael W, Krambeck, Amy E. , Terry, Colin, Matlaga, Brian R., Miller, Nicole L. , Humphreys, Mitchell R. , Gnessin, Ehud , Lingeman, James E., Miller, Nicole L

Mayo Clinic

Journal of Urology | June 21, 2010 | Volume: 184 | Issue: 2 | Pages: 635-640

10.1016/j.juro.2010.03.130 | PMID 20639029 Get It

Cerebellar Pleomorphic Xanthoastrocytoma
Wasdahl, Daniel A., Scheithauer, Bernd W., Jeffrey, Robert A., Andrews, Brian T.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 35 | Issue: 5 | Pages: 947-951

10.1227/00006123-199411000-00022 | PMID 7838347 Get It

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Sargent, Daniel J. , Marsoni, Silvia , Monges, Geneviève, Thibodeau, Stephen N. , Labianca, Roberto , French, Amy J. , Kabat, Brian, Foster, Nathan R. , Torri, Valter , Ribic, Christine, Moore, Malcolm , Zaniboni, Alberto , Seitz, J. F., Sinicrope, Frank, Gallinger, Steven , Hamilton, Stanley R. , Grothey, Axel , Sargent, Daniel J , Marsoni, Silvia

Mayo Clinic

Journal of Clinical Oncology | May 24, 2010 | Volume: 28 | Issue: 20 | Pages: 3219-3226

10.1200/jco.2009.27.1825 | PMID 20498393 Get It

Purpose Prior reports have indicated that patients with colon cancer who demonstrate high-level microsatellite instability (MSI-H) or defective DNA mismatch repair (dMMR) have improved survival and receive no benefit from fluorouracil (FU) -based adjuvant therapy compared with patients who have microsatellite-stable or proficient mismatch repair (pMMR) tumors. We examined MMR status as a predictor of adjuvant therapy benefit in patients with stages II and III colon cancer. Methods MSI assay or immunohistochemistry for MMR proteins were performed on 457 patients who were previously randomly assigned to FU-based therapy (either FU + levamisole or FU + leucovorin; n = 229) versus no postsurgical treatment (n = 228). Data were subsequently pooled with data from a previous analysis. The primary end point was disease-free survival (DFS). Results Overall, 70 (15%) of 457 patients exhibited dMMR. Adjuvant therapy significantly improved DFS (hazard ratio [HR], 0.67; 95% CI, 0.48 to 0.93; P = .02) in patients with pMMR tumors. Patients with dMMR tumors receiving FU had no improvement in DFS (HR, 1.10; 95% CI, 0.42 to 2.91; P = .85) compared with those randomly assigned to surgery alone. In the pooled data set of 1,027 patients (n = 165 with dMMR), these findings were maintained; in patients with stage II disease and with dMMR tumors, treatment was associated with reduced overall survival (HR, 2.95; 95% CI, 1.02 to 8.54; P = .04). Conclusion Patient stratification by MMR status may provide a more tailored approach to colon cancer adjuvant therapy. These data support MMR status assessment for patients being considered for FU therapy alone and consideration of MMR status in treatment decision making.